US OptionsDetailed Quotes
CASI241220P7500
- 0.00
- 0.000.00%
15min DelayClose Nov 29 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover319.36%IV-97.37%PremiumDec 20, 2024Expiry Date3.70Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7102Delta0.1230Gamma0.94Leverage Ratio-0.0241Theta-0.0029Rho-0.67Eff Leverage0.0030Vega
CASI Pharmaceuticals Stock Discussion
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
CASI Pharmaceuticals (NASDAQ:CASI) has received Clinical Trial Application (CTA) approval from China's NMPA to conduct a phase 1/2 study of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP). The China study is part of a global study previously approved by the US FDA in May 2024. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that...
$MicroCloud Hologram (HOLO.US)$ $Loop Media (LPTV.US)$ $CASI Pharmaceuticals (CASI.US)$ $Petco Health and Wellness (WOOF.US)$ $Clearmind Medicine (CMND.US)$ $Innovative Eyewear (LUCY.US)$
📊⚡️📊
just
Board Got a Preliminary Non-Binding Proposal Letter Dated June 21, From Wei-Wu He, Chairman of Board and CEO of Company
CASI Pharmaceuticals Inc - Proposed Deal for Purchase Price of $40.0 Mln, Which Shall Include Assumption of up to $20.0 Mln of Indebtedness of Company
No comment yet